Cargando…
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Multiple myeloma (MM) is an incurable hematological cancer, in which immune checkpoint inhibition (ICI) with monoclonal antibodies (mAbs) has failed due to uncontrollable immune responses in combination therapies and lack of efficacy in monotherapies. Although NK cell-specific checkpoint targets suc...
Autores principales: | Susek, Katharina H., Schwietzer, Ysabel A., Karvouni, Maria, Gilljam, Mari, Keszei, Marton, Hussain, Alamdar, Lund, Johan, Kashif, Muhammad, Lundqvist, Andreas, Ljunggren, Hans-Gustaf, Nahi, Hareth, Wagner, Arnika K., Alici, Evren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110653/ https://www.ncbi.nlm.nih.gov/pubmed/36355079 http://dx.doi.org/10.1007/s00262-022-03317-y |
Ejemplares similares
-
Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020) -
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019) -
The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment
por: Susek, Katharina Helene, et al.
Publicado: (2018) -
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022) -
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
por: Karvouni, Maria, et al.
Publicado: (2022)